Experimental multi-center validation of a radiomics-based photonic quantum precision medicine architecture for lesion-level prediction of anti-PD-1 response in non-small cell lung cancer
Preprint
Abstract
Background: Previous research has shown that radiomics-based machine learning models are promising precision medicine tools for lesion-level predictions of Anti-PD-1 response in advanced non-small cell lung cancer (NSCLC) but their clinical implementation remains limited due to poor generalizability and uncertainty about which features capture true biological signals or merely reflect noise. We tested the performance and multi-center validity of a radiomics-based photonic quantum architecture trained on a feature space reduced using clinical knowledge and robust medical statistics. Methods: This study included 125 patients with 164 advanced NSCLC single lesions from 3 different hospitals (Train, Test 1 and Test 2) treated with anti-PD1 monotherapy as first or second line. All patients underwent a baseline CT scan before the start of the treatment, the lesions were semi-automatically segmented and labeled as “progressive” if their diameter increased by more than 10% and as “non-progressive” if their diameter decreased by 10% or more over the following 6 months. From each CT scan we extracted 851 radiomic features with a METhodological RadiomICs Score (METRICS) of 86.1% (Excellent Quality Category (Table S1)) of which 183 were identified as reliable based on previous published clinical research. We then trained 1 classical and 3 photonic quantum machine learning models in Train Hospital and tested their performance on unseen external datasets in Test Hospitals 1 & 2. Aiming to explore quantum machine learning as a long-term technology for precision oncology, we utilized an ideal classical simulation of a photonic quantum architecture. This approach assumes perfectly functioning hardware, eliminating confounding physical noise to assess true theoretical performance. Crucially, by adapting the standardized MerLin template, we ensure our results are reproducible, fulfilling an essential requirement for evidence-based clinical research. Findings: We found that only 2 features out of 851 were both reliable and robustly correlated to the target ( p < 0.001). These 2 features were used to train the machine learning models. Across external validation datasets, the LEXGROUPING-6modes quantum architecture explicitly outperformed the classical MLP baseline in Test Hospital 1 (Average Precision 0.755 vs. 0.702) and matched its performance in Test Hospital 2 (0.670). Notably, all photonic quantum architectures successfully exceeded the chance level defined by progressor prevalence (0.622 and 0.462, respectively). Interpretation: To our knowledge, this is the first study that tests the external validity of radiomics-based photonic quantum architectures utilizing an evidence-based, statistically significant reduced feature space. Crucially, demonstrating that a quantum architecture can outperform or match an optimized classical baseline represents a significant milestone. These findings validate the theoretical potential of quantum models to capture complex biological signals, supporting their future role as clinical decision support systems for NSCLC immunotherapy as both dedicated quantum algorithms evolve and physical hardware matures. Furthermore, we found supporting evidence that heavily reducing the feature space can improve generalizability without compromising performance. Future research is required to assess scalability to other clinical centers and validate these models on physical photonic quantum processors under realistic hardware noise conditions.Keywords
This publication has 27 references indexed in Scilit:
- Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic reviewAnnals of Oncology, 2023
- An Explainable MRI-Radiomic Quantum Neural Network to Differentiate Between Large Brain Metastases and High-Grade Glioma Using Quantum Annealing for Feature SelectionJournal of Digital Imaging, 2023
- Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerJournal of Thoracic Oncology, 2021
- Uncertainty measurement of radiomics features against inherent quantum noise in computed tomography imagingEuropean Radiology, 2021
- Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extensionThe Lancet Digital Health, 2020
- A review of feature selection methods in medical applicationsComputers in Biology and Medicine, 2019
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint BlockadeJAMA Oncology, 2019
- Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysisLung Cancer, 2018
- Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patientsCancer Cytopathology, 2018
- Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLCJournal of Thoracic Oncology, 2017